Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26438869 | 0.83 | ACACB (0.41) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20047441 | 0.83 | GAA (0.41) | ACACBTRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20047448 | 0.79 | ALOX15 (0.39) | ACACBTRPV1ALDH1A1TP53MAPT | |
| SCHEMBL20048893 | 0.79 | SMN1; SMN2 (0.55) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL20043213 | 0.79 | CASR (0.37) | ACACBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2707208 | 0.77 | NPC1 (0.45) | ACACBTRPV1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20047532 | 0.76 | LIPG (0.39) | TRPV1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12269123 | 0.71 | TRPV1 (0.42) | TRPV1NPC1RAB9ASMN1; SMN2SCN4A | |
| SCHEMBL18596032 | 0.71 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL86109 | 0.71 | GAA (0.59) | NPC1RAB9ASMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | ACACB 419/4885TRPV1 956/4885NPC1 52/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | ACACB 419/4885TRPV1 956/4885NPC1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.